Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2007

View Archived Issues

AstraZeneca reviews development and regulatory advances of fourth quarter

Novel tubulin polymerization inhibitors identified at Threshold Pharmaceuticals

CNTO-1275 effective in phase II psoriasis trial

Lacosamide significantly reduces pain in peripheral diabetic neuropathy

New treatment option for urological disorders disclosed in recent Ranbaxy patent

Novel anticancer agents imparted in recent Novartis patent

Recent patents describe new therapeutic agents for neurological disorders

Recent patents describe novel analgesic agents

Long-acting octreotide to be investigated in polycystic liver disease

FG-4539 neuroprotective in stroke model

Studies support phase III investigations of ancrod in stroke

Kadian pharmacokinetics not significantly affected by alcohol

Forbes Medi-Tech restructures

Avanex announces preclinical oncology compounds

R-763 studied in phase I for hematological malignancies

Phase III clinical trial under way for LymphoStat-B in SLE

Poniard seeks to begin clinical testing of oral picoplatin

Elixir and Siena Biotech collaborate on SIRT1 inhibitors in Huntington's disease

BL-1020 successfully completes phase I trials for schizophrenia

Seattle Genetics awarded orphan drug designations for SGN-33 and SGN-35

GW and Otsuka establish strategic cannabinoid alliance

Hemospan studied in parallel European phase III trials

TG-4040 studied in phase I trial for chronic HCV

Silenor NDA filing on track for Q3 2007

ThromboView phase II DVT results confirm efficacy

DDP-733 produces statistically significant clinical response rate in IBS-c

AzaSite Plus well tolerated in phase I study

Replagal launching in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...